CIT 2018: MicroPort® Hosts Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®"

Suzhou, China – From March 22 to March 25, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 16th China Interventional Therapeutics ("CIT 2018") and hosted Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®", which attracted wide attention from the audience.
The FUTURE-I research is the First-In-Man ("FIM") study on Firesorb® Bioresorbable Sirolimus Target Eluting Coronary Scaffold System ("Firesorb®"). The study was a prospective single center study included 45 single coronary artery lesions of the subjects. All subjects received angiography and IVUS examination before coronary stents implantation, and underwent angiography, IVUS and OCT after operation, followed by two years of follow-up. The patients were divided into two cohorts, respectively received angiography, IVUS and OCT check again in six months and two years after operation (cohort 1) and one year, three years after operation (cohort 2). The main endpoint of the study is Target Lesion Failure. According to the result, the occurrence of the main endpoint in two years is zero, the occurrence of patient-oriented composite endpoint ("PoCE"), including death, myocardial infarction, and revascularization is 2.2%, and the occurrence of all-cause mortality, target vessel MI and stent thrombosis are all zero. Based on the two-year follow-up outcome, Firesorb® is one of the safe and effective solutions for patients with single-vessel coronary diseases.
During the session of bioabsorbable stent, Dr. Qiyi Luo introduced the design features of Firesorb®. Firesorb® bioabsorbable stent with polymer degradation in vivo poly-L-lactic acid ("PLLA") as the matrix material, poly D, L- lactide ("PDLLA") for drug balloon dilatation eluting stent of surface materials thickness is only 100-125μm, with low dose of Sirolimus as eluting drug, which is more light and with less degradation time. In the Innovation Summit, Dr. Qiyi Luo introduced the new products and new technologies under research to demonstrate MicroPort® is an innovative, high-tech medical device group.
On March 24, MicroPort® hosted Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®" chaired by Academician Runlin Gao of Fuwai Hospital of Chinese Academy of Medical Sciences, Dr. Alexandra Lansky of Yale University, Dr. Alfredo E. Rodriguez of Otamendi Hospital, Professor Zuyi Yuan of the First Affiliated Hospital of Xi'an Jiaotong University, and Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences.
Professor Andreas Baumbach released the three-month OCT result of Target AC Trial which shows the early healing effect of Firehawk® stents is non-inferior to that of the control group Xience stents. Afterwards, Professor Ankur Gupta and Professor Richard Anderson reviewed clinical cases of Firehawk®, which shows its excellent crossability and dilation ability. Professor Qi Zhang of East Hospital of Tongji University analyzed a case of Firehawk® treating left main disease under the guidance of intracavity imaging and physiological function examination, which further demonstrated the excellent performance of Firehawk®.
This conference fully demonstrated the excellent performance of Firehawk® and verified the safety and efficacy of Firehawk® and Firesorb® with evidence based medicine.